Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease tuberous sclerosis
Symptom C0205768|subependymal giant cell astrocytoma
Sentences 31
PubMedID- 25493579 subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mtor inhibitors.
PubMedID- 25227171 Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex.
PubMedID- 23743818 Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis.
PubMedID- 23325902 Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc).
PubMedID- 20133820 Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
PubMedID- 23391693 Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations.
PubMedID- 25143481 Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex.
PubMedID- 23158522 We assessed the efficacy and safety of everolimus in patients with subependymal giant cell astrocytomas associated with tuberous sclerosis complex.
PubMedID- 23138436 The authors describe a rare case of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex that presented with intratumoral bleeding with extension to the ventricles.
PubMedID- 25456370 Background: in the exist-1 trial, initiated on aug 10, 2009, more than 35% of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex had at least 50% reduction in sega volume after 9.6 months of treatment with everolimus.
PubMedID- 25682485 Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period.
PubMedID- 24105488 subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention.
PubMedID- 23686401 Everolimus is a mammalian target of rapamycin (mtor) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive her2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole.
PubMedID- 22805244 Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 24756805 Everolimus has been approved by the fda and the ema for the treatment of advanced renal cell carcinoma (rcc), subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (tsc), pancreatic neuroendocrine tumors (pnet), in combination with exemestane in advanced hormone-receptor (hr)-positive, her2-negative breast cancer.
PubMedID- 24667738 This analysis focuses on the clinical presentation, management, and associated burden of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex in the united states.
PubMedID- 24507694 Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
PubMedID- 24276039 Background: brain subependymal giant cell astrocytomas (segas) in patients with tuberous sclerosis have been reported to respond to everolimus.
PubMedID- 23231513 Everolimus (rad001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 21297924 From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas.
PubMedID- 23183057 The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex.
PubMedID- 24056156 Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of rapamycin inhibitors.
PubMedID- 23567018 Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 22136276 Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 26381530 Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619).
PubMedID- 25557360 Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
PubMedID- 22234227 Hemorrhagic subependymal giant cell astrocytoma in a patient with tuberous sclerosis: case report and review of the literature.
PubMedID- 20643042 subependymal giant cell astrocytoma in tuberous sclerosis complex.
PubMedID- 20422196 The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis.
PubMedID- 20887114 Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex.
PubMedID- 23788851 On the other hand, the mtor inhibitor rapamycin is found to be useful in tuberous sclerosis patients with subependymal giant cell astrocytomas.

Page: 1